LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

Search

Zai Lab Ltd ADR

Atidarymo kaina

SektoriusSveikatos priežiūra

32.17 4.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

30.78

Max

32.82

Pagrindiniai rodikliai

By Trading Economics

Pajamos

33M

-48M

Pardavimai

-2.6M

106M

Pelnas, tenkantis vienai akcijai

-0.45

Pelno marža

-45.487

Darbuotojai

1,869

EBITDA

19M

-56M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+70.22% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-241M

3.1B

Ankstesnė atidarymo kaina

27.65

Ankstesnė uždarymo kaina

32.17

Naujienos nuotaikos

By Acuity

23%

77%

38 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-18 23:47; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

2025-05-18 23:40; UTC

Rinkos pokalbiai

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

2025-05-18 18:00; UTC

Uždarbis

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

2025-05-18 17:01; UTC

Svarbiausios naujienos

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

2025-05-18 16:20; UTC

Uždarbis

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

2025-05-18 12:09; UTC

Svarbiausios naujienos

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

2025-05-17 17:15; UTC

Svarbiausios naujienos

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

2025-05-17 09:30; UTC

Svarbiausios naujienos
Uždarbis

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

2025-05-17 08:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-17 08:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-16 23:18; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

2025-05-16 22:30; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- Update

2025-05-16 21:56; UTC

Rinkos pokalbiai

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

2025-05-16 21:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-16 21:54; UTC

Svarbiausios naujienos

U.S. Loses Last Triple-A Credit Rating -- WSJ

2025-05-16 21:22; UTC

Rinkos pokalbiai

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

2025-05-16 21:17; UTC

Rinkos pokalbiai

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

2025-05-16 21:17; UTC

Svarbiausios naujienos

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

2025-05-16 21:05; UTC

Rinkos pokalbiai

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

2025-05-16 20:55; UTC

Įsigijimai, susijungimai, perėmimai

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025-05-16 20:50; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-05-16 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-16 20:37; UTC

Svarbiausios naujienos

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

2025-05-16 20:33; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

2025-05-16 20:30; UTC

Įsigijimai, susijungimai, perėmimai

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

2025-05-16 20:18; UTC

Svarbiausios naujienos

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

2025-05-16 20:16; UTC

Svarbiausios naujienos

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

2025-05-16 20:15; UTC

Uždarbis

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

2025-05-16 20:11; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: William K. Daniel Joins Board

2025-05-16 20:10; UTC

Įsigijimai, susijungimai, perėmimai

Henry Schein: Strategic Investment by KKR Completed

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

70.22% į viršų

12 mėnesių prognozė

Vidutinis 52.65 USD  70.22%

Aukščiausias 73 USD

Žemiausias 32.6 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

5

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

28.13 / 31.12Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

38 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.